T1	SNP 0 13	Polymorphisms
T2	Entity 17 42	tumour necrosis factors A
T3	Entity 17 40;47 48	tumour necrosis factors B
T4	Cancer 52 65	breast cancer
T5	Association 49 51	in
E1	Association:T5 bc:T4 snp_int:T1
R1	SNP_coupled_gene Arg1:T1 Arg2:T3	
R2	SNP_coupled_gene Arg1:T1 Arg2:T2	
T6	Spec 71 78	assayed
T7	SNP 83 123	germline single nucleotide polymorphisms
R3	Equiv Arg1:T7 Arg2:T1	
T8	Entity 138 142	TNFB
T9	Entity 147 151	TNFA
T10	Cancer 175 188	breast cancer
T11	Association 158 169	in patients
E2	Association:T11 snp_int:T7 bc:T10
R4	Speculation_marker Arg1:E2 Arg2:T6	
R5	SNP_coupled_gene Arg1:T7 Arg2:T8	
R6	SNP_coupled_gene Arg1:T7 Arg2:T9	
R7	Equiv Arg1:T8 Arg2:T3	
R8	Equiv Arg1:T9 Arg2:T2	
T12	SNP 92 123	single nucleotide polymorphisms
T13	SNP 125 129	SNPs
R9	Equiv Arg1:T13 Arg2:T12	
T14	Entity 216 228	first intron
T15	Entity 238 241	G/A
T16	Entity 250 255;308 323	-1031 promoter region
T17	Entity 257 260	T/C
T18	Entity 263 267;308 323	-863 promoter region
T19	Entity 269 272	C/A
T20	Entity 275 279;308 323	-857 promoter region
T21	Entity 281 284	C/T
T22	Entity 290 294;308 323	-308 promoter region
T23	Entity 296 299	G/A
R11	Member Arg1:T8 Arg2:T14	
R10	Nucleotide_substitution Arg1:T7 Arg2:T15	
R12	Nucleotide_substitution Arg1:T7 Arg2:T17	
R13	Nucleotide_substitution Arg1:T7 Arg2:T19	
R14	Nucleotide_substitution Arg1:T7 Arg2:T21	
R15	Nucleotide_substitution Arg1:T7 Arg2:T23	
R16	Member Arg1:T9 Arg2:T16	
R17	Member Arg1:T9 Arg2:T18	
R18	Member Arg1:T9 Arg2:T20	
R19	Member Arg1:T9 Arg2:T22	
T24	Cancer 635 648	Breast cancer
T25	Neg 653 656	not
T26	Association 657 667	associated
E3	Association:T26 bc:T24 snp_int:T27
R20	Negation_marker Arg1:E3 Arg2:T25	
T27	SNP 673 677	SNPs
T28	Entity 685 699	TNFA promoters
R21	SNP_coupled_gene Arg1:T27 Arg2:T28	
R22	Member Arg1:T28 Arg2:T16	
R23	Member Arg1:T28 Arg2:T18	
R24	Member Arg1:T28 Arg2:T20	
R25	Member Arg1:T28 Arg2:T22	
R26	Nucleotide_substitution Arg1:T27 Arg2:T23	
R27	Nucleotide_substitution Arg1:T27 Arg2:T19	
R28	Nucleotide_substitution Arg1:T27 Arg2:T17	
R29	Nucleotide_substitution Arg1:T27 Arg2:T21	
T29	Entity 430 454	TNFB*G/TNFB*G homozygote
T30	SNP 83 123	germline single nucleotide polymorphisms
R30	Genotype Arg1:T30 Arg2:T29	
T31	Entity 430 434	TNFB
R31	SNP_coupled_gene Arg1:T30 Arg2:T31	
T32	Association 486 497	predominant
E4	Association:T32 bc:T33 snp_int:T30
T33	Cancer 501 509	patients
T34	Cancer 365 387	breast cancer patients
R32	Equiv Arg1:T33 Arg2:T34	
T35	Entity 521 545	TNFB*A/TNFB*A homozygote
T36	Level 550 554	less
T37	Association 555 563	frequent
E5	Association:T37 bc:T38 snp_int:T40
T38	Cancer 567 575	patients
R33	Equiv Arg1:T38 Arg2:T34	
R34	Level_marker Arg1:E5 Arg2:T36	
A1	Level E5 Low
T39	Entity 521 525	TNFB
T40	SNP 83 123	germline single nucleotide polymorphisms
R35	SNP_coupled_gene Arg1:T40 Arg2:T39	
R36	Genotype Arg1:T40 Arg2:T35	
T41	Entity 714 718	TNFB
T42	SNP 719 722	SNP
R37	SNP_coupled_gene Arg1:T42 Arg2:T41	
T43	Entity 1015 1019	TNFB
T44	SNP 1020 1023	SNP
R38	SNP_coupled_gene Arg1:T44 Arg2:T43	
T45	Entity 1024 1037	TNFB*G/TNFB*G
R39	Genotype Arg1:T44 Arg2:T45	
T46	Effect_Type 1055 1064	increased
T47	Association 1065 1069	risk
E6	Association:T47 snp_int:T44 bc:T48
A2	Effect_Type E6 Increase
R40	Effect_type_marker Arg1:E6 Arg2:T46	
T48	Cancer 1074 1087	breast cancer
T49	Entity 1100 1113	TNFB*A/TNFB*A
T50	Association 1119 1129	resistance
E7	Association:T50 bc:T52 snp_int:T53
T51	Neg 1119 1129	resistance
R41	Negation_marker Arg1:E7 Arg2:T51	
T52	Cancer 1133 1146	breast cancer
T53	SNP 1020 1023	SNP
R42	SNP_coupled_gene Arg1:T53 Arg2:T43	
R43	Genotype Arg1:T53 Arg2:T49	
T54	Entity 1208 1214	TNFB*G
R44	SNP_allele Arg1:T44 Arg2:T54	
T55	Entity 1100 1106	TNFB*A
R45	SNP_allele Arg1:T53 Arg2:T60	
T56	Spec 1191 1198	suggest
T57	Patho_physiology 1245 1258	tumorigenesis
E8	Patho_physiology:T57 Agent:T44
T58	Cell_types_tissues_affected 1262 1272	activation
E9	Cell_types_tissues_affected:T58 Theme:T59 Agent:T44
T59	Entity 1276 1296	dormant tumour cells
R46	Speculation_marker Arg1:E8 Arg2:T56	
R47	Speculation_marker Arg1:E9 Arg2:T56	
T60	Entity 1306 1312	TNFB*A
T61	Patho_physiology 1374 1387	tumorigenesis
E10	Patho_physiology:T61 Agent:T53
T62	Effect_Type 1360 1370	inhibition
R48	Negation_marker Arg1:E10 Arg2:T62	
A3	Effect_Type E10 Decrease
R49	Speculation_marker Arg1:E10 Arg2:T56	
T63	SNP 871 874	SNP
T64	Entity 878 882	TNFA
R50	SNP_coupled_gene Arg1:T63 Arg2:T64	
T65	Patho_physiology 828 837	pathology
E11	Patho_physiology:T65 Theme:T66 Agent:T63
T66	Entity 844 857	tumour stages
T67	Level 802 824	substantial difference
A4	Level E11 High
R51	Level_marker Arg1:E11 Arg2:T67	
R52	SNP_location Arg1:T63 Arg2:T20	
R53	Nucleotide_substitution Arg1:T63 Arg2:T21	
T68	Neg 723 729	failed
T69	Patho_physiology 752 781	clinicopathological parameter
E12	Patho_physiology:T69 Agent:T42 Theme:T71
R54	Negation_marker Arg1:E12 Arg2:T68	
T71	Cancer 785 798	breast cancer
R55	SNP_location Arg1:T42 Arg2:T14	
R56	Nucleotide_substitution Arg1:T42 Arg2:T15	
T70	Patho_physiology 955 970	antitumorigenic
E13	Patho_physiology:T70 
R57	Equiv Arg1:E10 Arg2:E13	
T72	Patho_physiology 939 950	tumorigenic
E14	Patho_physiology:T72 
R58	Equiv Arg1:E8 Arg2:E14	
